AbbVie announced its first-quarter 2026 financial results, surpassing expectations with $15 billion in revenue and raising its full-year EPS guidance as next-generation immunology assets continue to offset Humira’s erosion.
AstraZeneca reports a robust start to 2026 with $15.3 billion in total revenue, driven by its powerhouse oncology and rare disease portfolios, alongside key clinical successes in COPD and hypophosphatasia.
Novartis reports a resilient Q1 2026 with major gains in oncology and immunology, despite expected generic competition in the US market.
Samsung Biologics reports a stellar start to 2026, recording KRW 1,257 billion in revenue and KRW 581 billion in operating profit, fueled by its new U.S. manufacturing presence and Plant 4 utilization.
Johnson & Johnson delivers a robust start to the year with the Johnson & Johnson Q1 2026 Results, reporting $24.1 billion in revenue and increasing its full-year earnings guidance amid major clinical approvals.
IQVIA reported $3.829 billion in total revenue for the first quarter that ended on March 31, 2025, a 2.5% increase over the same period in 2024.
Amgen Inc. (NASDAQ: AMGN) announced its financial results for the first quarter ended March 31, 2025, showcasing significant revenue growth fueled by strong product volume [Read More…]
Moderna, Inc. announced its financial results for the first quarter ending March 31, 2025, highlighting a strategic realignment towards oncology and other pipeline candidates amidst [Read More…]
Revenue reached $12.73 billion, a substantial 45% increase year-over-year, primarily fueled by strong volume growth from Mounjaro and Zepbound.
